COMPANY

Luminary Therapeutics

HQ: Minneapolis, MN source · luminarytx.com ↗ · Midwest

Keywords: oncology cell therapy solid tumor cancer CAR-T Multiple Myeloma in Relapse Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma Refractory/ Relapsed Multiple Myeloma Refractory B-cell Non-Hodgkin Lymphoma Multiple Myeloma in Remission Rheumatoid Arthritis Systemic Lupus Erthematosus Dermatomyositis Systemic Sclerosis Chronic Lymphocytic Leukemia Hairy Cell Leukemia Multiple Myeloma Systemic Lupus Erythematosus Refractory Multiple Myeloma ovarian carcinoma lupus BAFF CAR-T LMY-922 LMY-920 Autologous CAR-T cell therapy expressing the BAFF-ligand.

Location: Minneapolis, MN · source · Oct 15, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)5NIH grants

Funding and NIH signals

SEC Form D raise Raised $1.41M (Form D filed Nov 5, 2025). SEC Form D 0001437749-25-033325 (Nov 5, 2025)
Evidence (1 event)
- Nov 5, 2025 · SEC Form D 0001437749-25-033325
  Name of Issuer: Luminary Therapeutics, Inc.; CIK: 1793860; Address: Minneapolis, MN; Submission type: D; Filing date: 2025-11-05; Industry Group: Biotechnology; Date of First Sale: 2025-10-14; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 12388157; Total Amount Sold: 1406112; Federal exemptions: 06b
NIH award NIH awarded $587K (SBIR Phase II 5R44CA278021-03, continuation, notice Sep 10, 2026). NIH RePORTER 5R44CA278021-03 (Sep 10, 2026)
Evidence (1 event)
- Sep 10, 2026 · NIH RePORTER 5R44CA278021-03
  Organization: LUMINARY THERAPEUTICS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44CA278021-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 586799; Administering IC: National Cancer Institute; Project title: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

2026-12 Trial start Phase 2: BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma source ↗
2026-10 Trial start Phase 1: BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease source ↗
Sep 10, 2026 Grant Government grant — SBIR: $586,799 (annual award, as published), announced Sep 10, 2026. Agency: NIH/NCI. Source: government award database. source ↗
2026-09 Trial start Phase 1: BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies source ↗
Sep 23, 2025 Grant Government grant — SBIR: $1.46M (annual award, as published), announced Sep 23, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Apr 1, 2025 Trial start Phase 1: BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus source ↗
Mar 13, 2024 Trial start Phase 1: LMY-920 for Treatment of Relapsed or Refractory Myeloma source ↗
Nov 21, 2023 Trial start 1: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma source ↗

Upcoming milestones

2029-04 (ESTIMATED) · Phase 1 · BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies · NCT07679919
2030-03 (ESTIMATED) · Phase 1 · BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease · NCT07729995
2030-12 (ESTIMATED) · Phase 2 · BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma · NCT07771361

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Sep 10, 2026 Government grant — SBIR: $586,799 (annual award, as published), announced Sep 10, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 23, 2025 Government grant — SBIR: $1.46M (annual award, as published), announced Sep 23, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT07771361	BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma	Phase 2	Not yet recruiting	2026-12	2030-12 (estimated)
NCT07729995	BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease	Phase 1	Not yet recruiting	2026-10	2030-03 (estimated)
NCT07679919	BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies	Phase 1	Not yet recruiting	2026-09	2029-04 (estimated)
NCT06340750	BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus	Phase 1	Recruiting	Apr 1, 2025	Apr 15, 2026 (estimated)
NCT05312801	Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma	1	Recruiting	Nov 21, 2023	May 1, 2025 (estimated)
NCT05546723	LMY-920 for Treatment of Relapsed or Refractory Myeloma	Phase 1	Recruiting	Mar 13, 2024	Jul 31, 2025 (estimated)

NIH awards 5

Annual award amounts. Total $1.9M.

Sep 13, 2024 NIH award 1R43CA291415-01 FY2024: $399,256 awarded for that fiscal year; activity R43 (SBIR); PI HICKENLOOPER, SAMUEL; recipient as written: LUMINARY THERAPEUTICS, INC., MINNEAPOLIS, MN. An allogeneic gamma/delta arm source ↗
Aug 1, 2023 NIH award 1R43AI179375-01 FY2023: $299,770 awarded for that fiscal year; activity R43 (SBIR); PI GIBBONS, HUNTER RAMSDELL; recipient as written: LUMINARY THERAPEUTICS, INC., MINNEAPOLIS, MN. Allogeneic BAFF Ligand Ba source ↗
Jun 30, 2023 NIH award 1R44CA278021-01A1 FY2023: $397,934 awarded for that fiscal year; activity R44 (SBIR); PI LEWIS, ANDREW KYLE; recipient as written: LUMINARY THERAPEUTICS, INC., MINNEAPOLIS, MN. Allogeneic BAFF Ligand Based source ↗
Jul 19, 2021 NIH award 1R43CA254820-01A1 FY2021: $399,658 awarded for that fiscal year; activity R43 (SBIR); PI SHIRKEY-SON, NICOLE J.; recipient as written: LUMINARY THERAPEUTICS, INC., MINNEAPOLIS, MN. Simultaneous Targeting of source ↗
Sep 8, 2020 NIH award 1R43CA254794-01 FY2020: $397,422 awarded for that fiscal year; activity R43 (SBIR); PI DUNMIRE, SAMANTHA; recipient as written: LUMINARY THERAPEUTICS, INC., MINNEAPOLIS, MN. MyD88 fusion protein with antige source ↗